Gotham Asset Management LLC Purchases 2,812 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Gotham Asset Management LLC boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 38,953 shares of the biopharmaceutical company’s stock after purchasing an additional 2,812 shares during the period. Gotham Asset Management LLC’s holdings in Catalyst Pharmaceuticals were worth $813,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CPRX. Clark Capital Management Group Inc. bought a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $4,335,000. D. E. Shaw & Co. Inc. acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $379,000. EP Wealth Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $220,000. CoreCap Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 8,870.0% during the fourth quarter. CoreCap Advisors LLC now owns 35,880 shares of the biopharmaceutical company’s stock worth $749,000 after acquiring an additional 35,480 shares in the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of Catalyst Pharmaceuticals by 35.2% during the fourth quarter. Cetera Investment Advisers now owns 43,114 shares of the biopharmaceutical company’s stock worth $900,000 after acquiring an additional 11,221 shares during the period. 79.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CPRX. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Finally, Robert W. Baird boosted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $32.29.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 351,879 shares of company stock valued at $8,214,815. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $24.37 on Monday. The company’s 50-day moving average price is $23.23 and its two-hundred day moving average price is $22.48. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The stock has a market capitalization of $2.97 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.